ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
아바스틴(베바시주맙) 시장 규모는 향후 몇 년 동안 강력한 성장을 보일 것으로 예상됩니다. 예측 기간 동안의 성장은 인식 제고 및 조기 진단, 바이오시밀러 경쟁, 맞춤형 의약품의 성장, 의료 서비스의 접근성, 정밀 의학에 대한 강조의 증가에 기인할 수 있습니다. 예측 기간의 주요 동향으로는 복합 요법의 증가, 외래 환자 치료로의 전환, 환자 중심 치료 모델, 표적 치료의 채택 및 제품 혁신이 있습니다.
암의 유병률 증가는 향후 몇 년 동안 아바스틴(베바시주맙) 시장의 성장을 촉진할 것으로 예상됩니다. 암은 비정상적인 세포의 통제되지 않은 성장과 확산이 특징인 질병군을 말합니다. 암 발병률의 증가는 인구 고령화, 생활 방식의 변화, 진단 방법의 발전 등 여러 요인에 기인할 수 있습니다. 단일 클론 항체인 아바스틴은 VEGF를 억제하여 종양에 산소와 영양분을 공급하는 혈관 형성을 막아 종양 성장을 저해함으로써 암을 치료합니다. 예를 들어, 미국 암 협회는 2022년 미국에서 약 190만 건의 신규 암 사례와 60만 9,360건의 암 관련 사망이 예상되며, 이는 하루 평균 약 1,670명의 사망에 해당한다고 보고했습니다. 이처럼 증가하는 암 부담은 아바스틴 시장 확대의 주요 요인입니다.
아바스틴(베바시주맙) 시장의 성장은 의료비 지출의 증가에 의해 촉진될 것으로 예상됩니다. 의료비 지출은 건강 증진을 목적으로 하는 개인 위생, 예방 조치, 공중 보건 활동 등 건강 관련 상품 및 서비스에 대한 총 지출을 의미합니다. 이러한 증가는 인구 고령화, 만성 질환의 유행, 의료 기술의 발전, 의약품 가격의 상승, 비효율적인 지불 시스템, 의료 서비스에 대한 수요 증가 등의 요인에 의해 촉진되고 있습니다. 의료 지출의 증가는 보험 적용 범위 확대를 통해 아바스틴의 접근성을 높여 시장 확대와 환자 사용률을 촉진합니다. 예를 들어, 영국 국가통계청(ONS)의 2024년 5월 보고서에 따르면 2022년부터 2023년까지 총 의료 지출은 5.6% 증가했으며, 이는 2022년의 0.9% 성장률과 대비됩니다. 또한, 2022년에는 장기 의료 및 사회 복지 지출이 실질적으로 2.8% 증가했습니다. 이러한 동향은 의료 시스템에 대한 투자 증가가 아바스틴과 같은 혁신적인 치료법의 접근성과 성장을 지원하여 시장을 더욱 촉진하고 있음을 반영합니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 바이오의약품 시장에서의 제품 특성
분자 유형
투여경로(ROA)
작용기전(MOA)
안전성과 유효성
제4장 시장 동향과 전략
제5장 시장 : 금리, 인플레이션, 지정학, 무역 마찰, 코로나 패와 회복을 포함한 거시 경제의 영향
제6장 세계의 성장 분석과 전략 분석 프레임워크
세계의 아바스틴(베바시주맙) : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
최종 이용 산업의 분석
세계의 아바스틴(베바시주맙) 시장 : 성장률 분석
세계의 아바스틴(베바시주맙) 시장 실적 : 규모와 성장(2019-2024년)
세계의 아바스틴(베바시주맙) 시장 예측 : 규모와 성장(2024-2029년, 2034년)
세계의 아바스틴(베바시주맙) : 전체 시장 규모(TAM)
제7장 세계 시장의 가격 분석과 예측
제8장 시장 세분화
세계의 아바스틴(베바시주맙) 시장 : 투여량별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
100mg
400mg
세계의 아바스틴(베바시주맙) 시장 : 용도별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
비편평 상피 비소세포 폐암
재발성 신경교아종
자궁 경부암
대장암
난소암
증식성 당뇨병 망막증
악성 뇌종양
신경 섬유종증
췌장암
기타
세계의 아바스틴(베바시주맙) 시장 : 유통 채널별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
직접 입찰
병원 약국
소매 약국
온라인 약국
기타
세계의 아바스틴(베바시주맙) 시장 : 최종 사용자별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
병원
암 지원 센터
재택 의료
학술연구기관
기타
제9장 임상적응증 세계 시장 역학
약제의 부작용
임상적응증의 발병률과 유병률
제10장 지역별, 국가별 분석
세계의 아바스틴(베바시주맙) 시장 : 지역별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
세계의 아바스틴(베바시주맙) 시장 : 국가별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
제11장 아시아태평양 시장
제12장 중국 시장
제13장 인도 시장
제14장 일본 시장
제15장 호주 시장
제16장 한국 시장
제17장 서유럽 시장
제18장 영국 시장
제19장 독일 시장
제20장 프랑스 시장
제21장 동유럽 시장
제22장 북미 시장
제23장 미국 시장
제24장 캐나다 시장
제25장 남미 시장
제26장 중동 시장
제27장 아프리카 시장
제28장 경쟁 구도와 기업 프로파일
아바스틴(베바시주맙) 시장 : 경쟁 구도
아바스틴(베바시주맙) 시장 : 기업 프로파일
Roche Holding AG
제29장 세계 시장 : 파이프라인 분석
제30장 세계 시장 경쟁 벤치마킹과 대시보드
제31장 주요 인수합병(M&A)
제32장 최근 시장 동향
제33장 시장의 잠재력이 높은 국가, 전략
아바스틴(베바시주맙) 시장(2029년) : 새로운 기회를 제공하는 국가
아바스틴(베바시주맙) 시장(2029년) : 새로운 기회를 제공하는 부문
아바스틴(베바시주맙) 시장(2029년) : 성장 전략
시장 동향에 의한 전략
경쟁 전략
제34장 부록
HBR
영문 목차
영문목차
Avastin (bevacizumab) is a monoclonal antibody that targets vascular endothelial growth factor (VEGF), effectively inhibiting angiogenesis-the process by which new blood vessels are formed to supply tumors with oxygen and nutrients. It is commonly used in conjunction with chemotherapy to treat various cancers, including colorectal, lung, kidney, and glioblastoma.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The primary dosages of avastin (bevacizumab) are 100 mg and 400 mg. The 100 mg dosage form is used to treat a range of cancers by preventing the growth of blood vessels that nourish tumors. Its applications include non-squamous non-small cell lung cancer, recurrent glioblastoma, cervical cancer, colorectal cancer, ovarian cancer, proliferative diabetic retinopathy, malignant glioma, neurofibromatosis, pancreatic cancer, among others. These products are distributed through various channels such as direct tender, hospital pharmacies, retail pharmacies, and online pharmacies. End users include hospitals, cancer care centers, home healthcare providers, academic and research institutes, and others.
The avastin (bevacizumab) market research report is one of a series of new reports from The Business Research Company that provides Avastin (bevacizumab) market statistics, including the Avastin (bevacizumab) industry's global market size, regional shares, competitors with an Avastin (bevacizumab) market share, detailed Avastin (bevacizumab) market segments, market trends and opportunities, and any further data you may need to thrive in the Avastin (bevacizumab) industry. This Avastin (bevacizumab) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The avastin (bevacizumab) market size is expected to see strong growth in the next few years. It will grow to $10,489.0 million in 2029 at a compound annual growth rate (CAGR) of 9%. The growth in the forecast period can be attributed to increased awareness and early diagnosis, biosimilar competition, personalized medicine growth, healthcare accessibility, and growing emphasis on precision medicine. Major trends in the forecast period include increasing combination therapies, shift towards outpatient care, patient-centric treatment models, adoption of targeted therapies, and product innovation.
The increasing prevalence of cancer is expected to drive the growth of the avastin (bevacizumab) market in the coming years. Cancer encompasses a group of diseases characterized by the uncontrolled growth and spread of abnormal cells. The rising incidence of cancer can be attributed to factors such as aging populations, lifestyle changes, and advancements in detection methods. Avastin, a monoclonal antibody, treats cancer by inhibiting VEGF, preventing the formation of blood vessels that supply oxygen and nutrients to tumors, thereby impeding tumor growth. For instance, the American Cancer Society reported that in 2022, approximately 1.9 million new cancer cases and 609,360 cancer-related deaths were anticipated in the United States, equivalent to about 1,670 deaths daily. This rising cancer burden is a significant driver of the avastin market's expansion.
The growth of the Avastin (bevacizumab) market is expected to be propelled by rising healthcare expenditure. Healthcare expenditure encompasses the total spending on health-related goods and services, including personal care, preventive measures, and public health activities, aimed at enhancing health outcomes. This increase is driven by factors such as an aging population, the prevalence of chronic diseases, advancements in medical technology, high drug prices, inefficient payment systems, and a growing demand for healthcare services. Elevated healthcare expenditure facilitates greater access to Avastin through improved insurance coverage, thereby broadening its market reach and patient utilization. For example, a report by the UK's Office for National Statistics in May 2024 highlighted a 5.6% nominal increase in total healthcare expenditure from 2022 to 2023, compared to a 0.9% growth rate in 2022. Additionally, long-term health and social care spending rose by 2.8% in real terms in 2022. This trend reflects how increasing investment in healthcare systems supports the accessibility and growth of innovative treatments like Avastin, further driving the market forward.
A key trend shaping the avastin (bevacizumab) market is the development of biosimilars to provide cost-effective alternatives and improve access to cancer treatments. Biosimilars, highly similar in structure, function, and efficacy to Avastin, are transforming oncology care by offering affordable options, particularly in resource-constrained settings. For example, in October 2022, Amneal Pharmaceuticals launched ALYMSYS (bevacizumab-maly), a biosimilar referencing Avastin, in the U.S. This VEGF inhibitor is indicated for various cancers, including metastatic colorectal cancer, non-squamous non-small cell lung cancer, recurrent glioblastoma, renal cell carcinoma, and gynecologic cancers, demonstrating the potential of biosimilars to enhance treatment accessibility.
Key player operating in the avastin (bevacizumab) market is Roche Holding AG
North America was the largest region in the avastin (bevacizumab) market in 2024. The regions covered in avastin (bevacizumab) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the avastin (bevacizumab) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The avastin (bevacizumab) market consists of sales of intravenous (iv) formulations, and bevacizumab injection. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Avastin (Bevacizumab) Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on avastin (bevacizumab) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 10 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 3-4 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for avastin (bevacizumab) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The avastin (bevacizumab) market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Dosage: 100 Mg; 400 Mg
2) By Application: Non Squamous Non-Small Cell Lung Cancer; Recurrent Glioblastoma; Cervical Cancer; Colorectal Cell Cancer; Ovarian Cancer; Proliferative Diabetic Retinopathy; Malignant Glioma; Neurofibromatosis; Pancreatic Cancer; Other Applications
3) By Distribution channel: Direct Tender; Hospital Pharmacy; Retail Pharmacy; Online Pharmacy; Other Distribution Channels
4) By End User: Hospitals; Cancer Supportive Centers; Home Healthcare; Academic And Research Institutes; Other End Users
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Avastin (Bevacizumab) Market Characteristics
3. Avastin (Bevacizumab) Market Biologic Drug Characteristics
3.1. Molecule Type
3.2. Route Of Administration (ROA)
3.3. Mechanism Of Action (MOA)
3.4. Safety And Efficacy
4. Avastin (Bevacizumab) Market Trends And Strategies
5. Avastin (Bevacizumab) Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market
6. Global Avastin (Bevacizumab) Growth Analysis And Strategic Analysis Framework
6.1. Global Avastin (Bevacizumab) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
6.2. Analysis Of End Use Industries
6.3. Global Avastin (Bevacizumab) Market Growth Rate Analysis
6.4. Global Avastin (Bevacizumab) Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
6.5. Global Avastin (Bevacizumab) Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
6.6. Global Avastin (Bevacizumab) Total Addressable Market (TAM)
7. Global Avastin (Bevacizumab) Market Pricing Analysis & Forecasts
8. Avastin (Bevacizumab) Market Segmentation
8.1. Global Avastin (Bevacizumab) Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
100 Mg
400 Mg
8.2. Global Avastin (Bevacizumab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Non Squamous Non-Small Cell Lung Cancer
Recurrent Glioblastoma
Cervical Cancer
Colorectal Cell Cancer
Ovarian Cancer
Proliferative Diabetic Retinopathy
Malignant Glioma
Neurofibromatosis
Pancreatic Cancer
Other Applications
8.3. Global Avastin (Bevacizumab) Market, Segmentation By Distribution channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Direct Tender
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Other Distribution Channels
8.4. Global Avastin (Bevacizumab) Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Cancer Supportive Centers
Home Healthcare
Academic And Research Institutes
Other End Users
9. Global Avastin (Bevacizumab) Market Epidemiology Of Clinical Indications
9.1. Drug Side Effects
9.2. Incidence And Prevalence of Clinical Indications
10. Avastin (Bevacizumab) Market Regional And Country Analysis
10.1. Global Avastin (Bevacizumab) Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. Global Avastin (Bevacizumab) Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
11.2. Asia-Pacific Avastin (Bevacizumab) Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Asia-Pacific Avastin (Bevacizumab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Asia-Pacific Avastin (Bevacizumab) Market, Segmentation By Distribution channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. China Avastin (Bevacizumab) Market
12.1. China Avastin (Bevacizumab) Market Overview
12.2. China Avastin (Bevacizumab) Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
12.3. China Avastin (Bevacizumab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
12.4. China Avastin (Bevacizumab) Market, Segmentation By Distribution channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
13. India Avastin (Bevacizumab) Market
13.1. India Avastin (Bevacizumab) Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. India Avastin (Bevacizumab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. India Avastin (Bevacizumab) Market, Segmentation By Distribution channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. Japan Avastin (Bevacizumab) Market
14.1. Japan Avastin (Bevacizumab) Market Overview
14.2. Japan Avastin (Bevacizumab) Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. Japan Avastin (Bevacizumab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. Japan Avastin (Bevacizumab) Market, Segmentation By Distribution channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Australia Avastin (Bevacizumab) Market
15.1. Australia Avastin (Bevacizumab) Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.2. Australia Avastin (Bevacizumab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Australia Avastin (Bevacizumab) Market, Segmentation By Distribution channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. South Korea Avastin (Bevacizumab) Market
16.1. South Korea Avastin (Bevacizumab) Market Overview
16.2. South Korea Avastin (Bevacizumab) Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. South Korea Avastin (Bevacizumab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.4. South Korea Avastin (Bevacizumab) Market, Segmentation By Distribution channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Western Europe Avastin (Bevacizumab) Market
17.1. Western Europe Avastin (Bevacizumab) Market Overview
17.2. Western Europe Avastin (Bevacizumab) Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Western Europe Avastin (Bevacizumab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.4. Western Europe Avastin (Bevacizumab) Market, Segmentation By Distribution channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. UK Avastin (Bevacizumab) Market
18.1. UK Avastin (Bevacizumab) Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. UK Avastin (Bevacizumab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. UK Avastin (Bevacizumab) Market, Segmentation By Distribution channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Germany Avastin (Bevacizumab) Market
19.1. Germany Avastin (Bevacizumab) Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Germany Avastin (Bevacizumab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Germany Avastin (Bevacizumab) Market, Segmentation By Distribution channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. France Avastin (Bevacizumab) Market
20.1. France Avastin (Bevacizumab) Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. France Avastin (Bevacizumab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. France Avastin (Bevacizumab) Market, Segmentation By Distribution channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Avastin (Bevacizumab) Market
21.1. Eastern Europe Avastin (Bevacizumab) Market Overview
21.2. Eastern Europe Avastin (Bevacizumab) Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Avastin (Bevacizumab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Avastin (Bevacizumab) Market, Segmentation By Distribution channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. North America Avastin (Bevacizumab) Market
22.1. North America Avastin (Bevacizumab) Market Overview
22.2. North America Avastin (Bevacizumab) Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. North America Avastin (Bevacizumab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.4. North America Avastin (Bevacizumab) Market, Segmentation By Distribution channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. USA Avastin (Bevacizumab) Market
23.1. USA Avastin (Bevacizumab) Market Overview
23.2. USA Avastin (Bevacizumab) Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. USA Avastin (Bevacizumab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. USA Avastin (Bevacizumab) Market, Segmentation By Distribution channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
